Libetavimab Injection has recently been officially approved for market launch, marking a significant advancement in China’s antiviral biologics sector. This humanized monoclonal antibody was co-developed by Livzon Pharmaceutical Group and the Institute of Microbiology, Chinese Academy of Sciences. It is primarily indicated for the treatment of lower respiratory tract infections caused by respiratory syncytial virus (RSV), particularly in high-risk infants and elderly patients. Clinical trial data demonstrate that Libetavimab significantly reduces hospitalization rates and severe disease incidence associated with RSV infection, showing favorable safety and tolerability. As China’s first domestically developed anti-RSV monoclonal antibody, its market approval not only fills a critical gap in domestic RSV therapeutics but also offers a novel Chinese solution to global RSV prevention and control. The drug is expected to be included in China’s national reimbursement drug list in the future, enhancing accessibility and benefiting a broader patient population.
立贝韦塔单抗注射液（Libetavimab Injection）近日正式获批上市，标志着我国在抗病毒生物制剂领域取得重要进展。该药物是一种人源化单克隆抗体，由丽珠集团与中科院微生物研究所联合研发，主要用于治疗由呼吸道合胞病毒（RSV）引起的下呼吸道感染，尤其适用于高风险婴幼儿及老年患者。临床试验数据显示，立贝韦塔单抗能显著降低RSV感染导致的住院率和重症发生率，具有良好的安全性和耐受性。作为我国首个自主研发的抗RSV单抗药物，其上市不仅填补了国内相关治疗领域的空白，也为全球RSV防控提供了新的中国方案。未来，该药物有望纳入国家医保目录，进一步提升可及性，惠及更多患者。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/20422.html